Drug patent cliffs arent just legal eventstheyre data events.
Most teams still treat patent expiration and litigation risk like a calendar problem: When does the patent end? and Whos likely to sue?
But the competitive edge is shifting. The companie…

Patent thickets arent just a legal inconveniencetheyre a business model. When a brands portfolio sprawls across overlapping Orange Book listings, method-of-use claims, formulation patents, and ever-shifting exclusivities, the simple path to generic ent…

Blockbuster drugs dont just have patentsthey have recipes. And if youre trying to build a competitive design-around, the real battleground isnt the active ingredient. Its the formulation.
Drug developers have long known that patents can be a maze of cl…

Pharma boards dont just oversee pipelines anymorethey oversee patent risk as a financial instrument.
Heres the uncomfortable truth: IP litigation isnt a legal event. Its a governance event. And the companies that treat it that way are the ones that tra…

Designing around formulation patents isnt just legal strategyits product strategy.
In generic drug development, the hardest part isnt always finding a molecule that can be made. Its building a path to market when the original innovator has protected …

Pharma forensics is having a momentand its not just for patent lawyers.
In a market where launch timing can be worth billions, the real competitive advantage often isnt the molecule. Its the lifecycle strategy: the formulation tweaks, the manufacturing…

Generic developers dont lose to brand strength. They lose to patent design.
For years, the industrys playbook has been straightforward: wait for primary patents to expire, file the generic, and let the litigation play out. But the market has matureda…

Patent cliffs arent just a legal eventtheyre a supply-chain stress test.
If you work in pharma operations, procurement, or commercial planning, youve probably felt it: the quiet months before the cliff, followed by the sudden scramble to secure product…

AI is great at finding what you already know to search for. The real advantage is finding what you didnt know existed.
In patent workespecially in chemical and biologicshidden prior art isnt just a buzzword. Its the difference between a clean freedom-t…

Most design-around strategies fail because they start with chemistrynot claims.
In pharma, the phrase design around sounds like a clever scientific workaround. In practice, its an IP chess match where the board is the patent claim set, the clock is r…